India 2026 Regulatory Update: G.S.R. 515(E) and IVD Import Guidance

1. Key takeaways

Two significant Indian device documents of 2026 are currently both in draft stage and not yet in force. The first is G.S.R. 515(E) (signed 2026-06-23, published 2026-06-24, with a 30-day consultation period running to 2026-07-22), which proposes to compress the Class B manufacturing licence timeline from 140 days to 115 days and the Class C/D timeline from 105 days to 90 days. The second is the Draft Guidance for the Import of In Vitro Diagnostic Medical Devices (No. CDSCO/IVD/GD/DRAFT/IMP/01/2026), which confirms that MD-14 proceeds through the MD Online portal with a 270-day timeline, and MD-16 through the NSWS portal with a 30-day timeline. Neither document changes what companies must demonstrate; both change how fast the process runs and where filings will be checked.

• G.S.R. 515(E) proposes amendments to Rules 20, 21, 23 and 25, compressing the licence review chain rather than adding technical requirements.
• The draft sets new non-conformity closure windows: 20 days for Class B and 15 days for Class C/D, starting only after the manufacturer submits its corrective report.
• The IVD import draft guidance fixes MD-14 at 270 days via MD Online and MD-16 at 30 days via NSWS, and lists common deficiencies.
• The Ministry of Health and Family Welfare described the proposed amendments as intended to simplify and speed up the manufacturing licence process.
• The statutory 9-month import period is untouched: the drafts move only the manufacturing chain, and the 270-day import figure aligns with Rule 36(1).

2. Legal basis

Both documents derive their force from the Drugs and Cosmetics Act, 1940 framework, and both are drafts whose final content may still change. The table below records each document’s number, status and content as published, together with the sources behind each line.

The status distinction in this table governs everything else: rows describing the drafts are descriptions of proposals, not of current law, and until a final gazette notification appears, the existing timelines — 140 and 105 days for manufacturing licences — remain the operative figures.

3. Expert insights

Insight one: G.S.R. 515(E) is a procedural amendment, not a substantive one. It introduces no new technical standards, no new testing requirements and no new labelling obligations; what it changes is time. After it takes effect, what companies need to upgrade is not their level of compliance but their speed of response. A dossier that met the standard under a 140-day clock still meets the standard under a 115-day clock, but the same internal review, query handling and document assembly must now fit into a shorter window, and every weakness in the process is magnified by the compression.

Insight two: the real pressure on companies comes from the new non-conformity closure windows. The draft creates closure windows of 20 days for Class B and 15 days for Class C/D, and the clock starts only after the manufacturer submits its corrective report. This means the company must have an internal corrective-action process capable of rapid mobilisation: the window measures the production of the report, not the waiting before it. A deficiency response that takes six weeks to draft was tolerable under the old timeline; under the draft it consumes the entire window before the report exists.

Insight three: the most valuable part of the IVD guidance draft is the list of common deficiencies. It names: signatory inconsistency with the cover letter; inconsistency of product name, model or manufacturing address between the PoA, the FSC and the labelling; foreign-language documents without certified translations; omission of site fees for new products; and insufficient fees for high-risk categories. This list is itself a self-check table. Even before the guidance is finalised, the deficiency types it names are the ones CDSCO is actually finding, which makes it usable today in a way the rest of the draft is not.

Insight four: the drafts leave the 9-month import period untouched. G.S.R. 515(E) moves only the manufacturing chain. The 270-day import figure is confirmed in the IVD guidance draft and is consistent with Rule 36(1). Companies whose India exposure is import-only should therefore read the 2026 drafts as a speed change on the manufacturing side and a channel-and-checklist clarification on the import side, not as a change in the overall import timeline they have already planned against.

4. Practical recommendations

• Apply the three do-nots: do not treat the drafts as current rules, do not quote the draft timelines to clients as commitments, and do not adjust quotations on the basis of the drafts.
• Apply the three dos: track the point at which each draft converts into a final notification, pre-build the internal response capability in the direction the drafts indicate, and use the IVD guidance draft’s deficiency list as a pre-submission self-check table.
• Note that the third item is immediately usable: even though the guidance itself is not finalised, the error types on the list are the ones CDSCO is genuinely finding in review.
• Build the corrective-action workflow so that a deficiency report can be produced within 15–20 days of receiving the findings, matching the draft’s closure windows.
• Keep the current 140/105-day manufacturing timelines in all live project plans until a final notification replaces them, and record the consultation deadline of 2026-07-22 as the tracking anchor for G.S.R. 515(E).

The discipline behind the three do-nots and three dos is the same: drafts are planning inputs, not commitments. The company that tracks them prepares its capabilities without betting its schedule on a gazette notification that has not yet appeared.

5. Verification checklist

• ☐ The team knows G.S.R. 515(E) is a draft and the current 140/105-day timelines continue to apply
• ☐ The conversion of the draft into a final notification is being tracked (consultation period to 2026-07-22)
• ☐ A 15–20 day corrective response capability has been pre-built in the direction of the draft
• ☐ The IVD guidance draft’s deficiency list is used as a pre-submission self-check table
• ☐ No external material describes the drafts as current rules

Regulatory information verified as of 27 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including India. Our team prepares dossiers to CDSCO expectations, manages SUGAM submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com